Lv52
1454 积分 2024-09-13 加入
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
6天前
已完结
An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
12天前
已完结
Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3/TL1A axis in inflammatory bowel disease
1个月前
已完结
Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3/TL1A axis in inflammatory bowel disease
1个月前
已完结
Should Glucokinase be Given a Chance in Diabetes Therapeutics? A Clinical-Pharmacological Review of Dorzagliatin and Lessons Learned So Far
1个月前
已完结
Prevention of Autoimmune Diabetes With Nonactivating Anti-CD3 Monoclonal Antibody
1个月前
已完结
1型糖尿病管理相关技术应用中国专家共识
1个月前
已完结
Type 1 diabetes mellitus prevention: present and future
1个月前
已完结
Type 1 Diabetes
1个月前
已关闭
Type 1 Diabetes
1个月前
已关闭
皖公网安备34019202002308
